These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 34915496)

  • 1. Mepolizumab Is an Effective Option in Severe Eosinophilic Asthma Regardless of Baseline Features: Single-Center Real-Life Data.
    Özdel Öztürk B; Yavuz Z; Eraslan D; Mungan D; Demirel YS; Aydın Ö; Sin BA; Bavbek S
    Int Arch Allergy Immunol; 2022; 183(5):526-538. PubMed ID: 34915496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of Low-Dose Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA): A Real-Life Experience.
    Özdel Öztürk B; Yavuz Z; Aydın Ö; Mungan D; Sin BA; Demirel YS; Bavbek S
    Int Arch Allergy Immunol; 2022; 183(12):1281-1290. PubMed ID: 36126640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the Clinical Features and Laboratory Data of Patients with Severe Eosinophilic Asthma Classified as Super-Responders, Partial Responders, or Nonresponders to Mepolizumab Treatment: A Real-Life Study.
    Cakmak ME; Öztop N; Yeğit OO; Özdedeoğlu Ö
    Int Arch Allergy Immunol; 2023; 184(8):736-743. PubMed ID: 36996772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of Mepolizumab in Patients with Severe Eosinophilic Asthma with/without Nasal Polyposis: A Real-Life Study.
    Bravo-Gutiérrez FJ; Miralles-López JC; Valverde-Molina J; Alemany Francés ML; Andújar-Espinosa R; Castilla-Martínez M; Avilés-Inglés MJ; Mora-González A; Pajarón-Fernández MJ; Cabrejos-Perotti S; Meseguer-Arce J; Flores Martín I; Pérez-Fernández V;
    Int Arch Allergy Immunol; 2024; 185(3):253-259. PubMed ID: 38035559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of mepolizumab treatment in oral corticosteroid-dependent severe eosinophilic asthma patients with chronic rhinosinusitis with nasal polyps: single center, real life study.
    Yilmaz I; Türk M; Nazik Bahçecioğlu S; Tutar N; Gülmez I
    Turk J Med Sci; 2020 Apr; 50(2):433-441. PubMed ID: 32093447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Effectiveness and the Characteristics of a "Super-Responder" to Mepolizumab in Severe Eosinophilic Asthma.
    Kavanagh JE; d'Ancona G; Elstad M; Green L; Fernandes M; Thomson L; Roxas C; Dhariwal J; Nanzer AM; Kent BD; Jackson DJ
    Chest; 2020 Aug; 158(2):491-500. PubMed ID: 32275980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study.
    Domingo Ribas C; Carrillo Díaz T; Blanco Aparicio M; Martínez Moragón E; Banas Conejero D; Sánchez Herrero MG;
    Drugs; 2021 Oct; 81(15):1763-1774. PubMed ID: 34586602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Real-World Outcomes of Mepolizumab and Benralizumab Among Biologic-Naive Patients With Severe Eosinophilic Asthma: Experience of 3 Years' Therapy.
    Fyles F; Nuttall A; Joplin H; Burhan H
    J Allergy Clin Immunol Pract; 2023 Sep; 11(9):2715-2723. PubMed ID: 37245734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results in clinical practice in the treatment of severe eosinophilic asthma with mepolizumab: a real-life study.
    Enríquez-Rodríguez AI; Hermida Valverde T; Romero Álvarez P; López-González FJ; Gullón Blanco JA; Expósito Villegas AR; Escobar Fernández MJ; Beristáin Urquiza AM; Alonso Fernández MÁ; Gutiérrez Rodríguez M; Castaño De Las Pozas G; Jiménez Pérez J; Fernández Mellado R; García Clemente MM; Casan Clara P
    J Asthma; 2022 May; 59(5):1005-1011. PubMed ID: 33653213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
    Ortega HG; Yancey SW; Mayer B; Gunsoy NB; Keene ON; Bleecker ER; Brightling CE; Pavord ID
    Lancet Respir Med; 2016 Jul; 4(7):549-556. PubMed ID: 27177493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mepolizumab effectiveness and identification of super-responders in severe asthma.
    Harvey ES; Langton D; Katelaris C; Stevens S; Farah CS; Gillman A; Harrington J; Hew M; Kritikos V; Radhakrishna N; Bardin P; Peters M; Reynolds PN; Upham JW; Baraket M; Bowler S; Bowden J; Chien J; Chung LP; Grainge C; Jenkins C; Katsoulotos GP; Lee J; McDonald VM; Reddel HK; Rimmer J; Wark PAB; Gibson PG
    Eur Respir J; 2020 May; 55(5):. PubMed ID: 32139455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effectiveness of mepolizumab in patients with severe eosinophilic asthma: In a real life study].
    Bulut İ; Yegin Katran Z; Yavuz D; Yıldız AB; Yakut T; Örçen C; Mersin SS
    Tuberk Toraks; 2023 Jun; 71(2):148-155. PubMed ID: 37345397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study.
    McDowell PJ; Diver S; Yang F; Borg C; Busby J; Brown V; Shrimanker R; Cox C; Brightling CE; Chaudhuri R; Pavord ID; Heaney LG;
    Lancet Respir Med; 2021 Oct; 9(10):1174-1184. PubMed ID: 33971168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the General Characteristics of Patients with Severe Asthma Who Switched from Omalizumab to Mepolizumab versus Patients Who Responded to Omalizumab Treatment: A Real-Life Study.
    Cakmak ME; Öztop N; Yeğit OO
    Int Arch Allergy Immunol; 2024; 185(2):158-166. PubMed ID: 37992693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mepolizumab improves sino-nasal symptoms and asthma control in severe eosinophilic asthma patients with chronic rhinosinusitis and nasal polyps: a 12-month real-life study.
    Detoraki A; Tremante E; D'Amato M; Calabrese C; Casella C; Maniscalco M; Poto R; Brancaccio R; Boccia M; Martino M; Imperatore C; Spadaro G
    Ther Adv Respir Dis; 2021; 15():17534666211009398. PubMed ID: 33910399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of mepolizumab in patients with severe eosinophilic asthma: results from real-world clinical practice in Finland.
    Koistinen V; Kauppi P; Idänpään-Heikkilä J; Veijalainen L; Iso-Mustajärvi I; Ylisaukko-Oja T; Mehtälä J; Viinanen A; Kilpeläinen M
    J Asthma; 2022 Dec; 59(12):2375-2385. PubMed ID: 35094632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mepolizumab in Severe Eosinophilic Asthma: A 2-Year Follow-Up in Specialized Asthma Clinics in Greece: An Interim Analysis.
    Kallieri M; Zervas E; Katsoulis K; Fouka E; Porpodis K; Samitas K; Papaioannou AI; Kipourou M; Gaki E; Vittorakis S; Markatos M; Dimakou K; Ampelioti S; Koukidou S; Makris M; Ntakoula M; Mitrova MH; Glynos K; Antoniou KM; Gaga M; Tzanakis N; Markopoulou K; Papakosta D; Bakakos P; Loukides S
    Int Arch Allergy Immunol; 2020; 181(8):613-617. PubMed ID: 32570256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mepolizumab for severe eosinophilic asthma: a real-world snapshot on clinical markers and timing of response.
    Caminati M; Cegolon L; Vianello A; Chieco Bianchi F; Festi G; Marchi MR; Micheletto C; Mazza F; Tognella S; Senna G
    Expert Rev Respir Med; 2019 Dec; 13(12):1205-1212. PubMed ID: 31592700
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy and safety of mepolizumab in a real-world cohort of patients with severe eosinophilic asthma.
    Pertzov B; Unterman A; Shtraichman O; Shitenberg D; Rosengarten D; Kramer MR
    J Asthma; 2021 Jan; 58(1):79-84. PubMed ID: 31479312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world outcomes of mepolizumab treatment in severe eosinophilic asthma patients - retrospective cohort study in Slovakia.
    Jesenak M; Vanecek V; Ondrusova M; Urdova V; Dostalova K; Hochmuth L
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2023 Sep; 167(3):272-280. PubMed ID: 37439266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.